Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Recurrence 1

Interventions

Cyclophosphamide 211Rituximab 193fludarabine 134fludarabine phosphate 91Vincristine 78Cytarabine 66Etoposide 65Doxorubicin 61Dexamethasone 60Lenalidomide 59venetoclax 56ibrutinib 55Prednisone 54Bendamustine Hydrochloride 51obinutuzumab 48Filgrastim 46Bortezomib 46Specimen Handling 42pembrolizumab 39Gemcitabine 39Methotrexate 38Melphalan 38Biopsy 38Peripheral Blood Stem Cell Transplantation 32Magnetic Resonance Spectroscopy 32Azacitidine 31Vorinostat 29Nivolumab 29Calcium Dobesilate 29Clofarabine 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Drug Evaluation × Lymphoid × Clear all
NCT04500587 2024-09-19

Phase 1 First in Human Study of ZN-d5 as a Single Agent

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 1 Completed
39 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute

NCT05758610 2024-05-08

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Shengke Pharmaceuticals (Jiangsu) Limited, China

Phase 1 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡